Kreatech Biotechnology BV* (the Netherlands)
Kreatech will use Ambion technology in development of a solution for gene expression analysis
Ambion will provide its MessageAmp II a RNA amplification system under the supply agreement, terms of which were not disclosed (6/27)
Cytochemia AG* (Germany)
Cytochemia got exclusive rights to market Striant SR in Germany
Striant SR is a mucoadhesive buccal testosterone treatment for hypogonadism; Ardana gets an up-front payment and ongoing suppy revenues (6/16)
Promega will hold a worldwide nonexclusive license to make and sell DNA-directed RNAi- based research products
Promega will receive a cash payment and continued royalties from certain sub- licenses; the agreement is part of a settled contract dispute (8/22)
Genentech is purchasing Biogen Idec's biologics for the facility, and is expected to offer manufacturing facility in Oceanside, Calif.
Genentech will pay about $408M in cash jobs to the 403 employees at the facility (6/16)
Auxilium Pharmaceuticals Inc. (AUXL)
Cobra will manufacture and supply AA4500 for Phase II/III trials
Auxilium is developing the protein drug for Peyronie's disease and Dupuytren's disease; the value of the deal exceeds $3.3M through 2006 (8/2)
Planet Biotechnology Inc.*
They expanded a deal to extract and purify Planet's CaroRx
The deal expands on a July 2004 agreemment covering the plant-made antibody; terms were not disclosed (7/12)
Omnia will provide Lentigen access to its cGMP facilities and services
The deal focuses on development of Omnia's Lentiviral vector gene delivery technology; terms were not disclosed (8/17)
AFG Biosolutions Inc.*
Omnia will provide AFG with manufacturing and product development services.
AFG works on products against potential biological weapons; details on the deal were not disclosed (7/19)
Tm will supply custom Tag-It reagents to InterGenetics for OncoVue under a five-year deal
InterGenetics is expected to buy at least $7.5M in reagents over the five years; Oncovue is a genetic-based breast cancer risk test (6/30)
Paladin Labs Inc. (Canada; TSE:PLB)
Deal to commercialize Twinject in Canada
The product is an epinephrine auto-injector approved in Canada for emergency treatment of severe allergic reactions; terms of the deal were not disclosed (7/27)
* Private companies are indicated with an asterisk.
Unless otherwise noted, stock symbols listed are on the Nasdaq market.
AIM = Alternative Investment Market; ASX = Australian Stock Market; LSE = London Stock Exchange; NYSE = New York Stock Exchange; TSE = Toronto Stock Exchange